Today: 19 March 2026
Subscribe
Browse Category

AMS:AEG 10 December 2025

Top US Stock Losers Today (December 10, 2025): Why Polestar, AeroVironment, Aegon and Other Names Are Sinking

Top US Stock Losers Today (December 10, 2025): Why Polestar, AeroVironment, Aegon and Other Names Are Sinking

Polestar shares plunged 23.5% intraday Wednesday, leading US stock decliners, as funding concerns deepened. Major indexes were flat ahead of the Federal Reserve’s rate decision, with the Dow near 47,650 and S&P 500 around 6,841. High-beta growth stocks, EV names, and resource plays saw sharp drops, while most S&P 500 losses remained modest. Traders awaited signals from Fed Chair Jerome Powell on inflation and policy.
10 December 2025
······
Top Pre‑Market Losers Today (December 10, 2025): AFJK, CBRL, DNLI & AEG Lead Early Declines Before the Bell

Top Pre‑Market Losers Today (December 10, 2025): AFJK, CBRL, DNLI & AEG Lead Early Declines Before the Bell

Aimei Health Technology plunged nearly 50% in pre-market trading after extending its business-combination deadline. Lion Group Holding and JX Luxventure Group each dropped over 35%. Broader U.S. stock futures showed little movement as investors awaited the Federal Reserve’s rate decision later today. Cracker Barrel and Denali Therapeutics also traded lower on fresh news and analyst calls.
10 December 2025
····

Stock Market Today

  • OKYO Pharma Chairman Gabriele Cerrone Increases Stake with Share Purchase
    March 19, 2026, 12:29 PM EDT. OKYO Pharma Limited (NASDAQ: OKYO) announced Chairman and Founder Gabriele Cerrone, through Panetta Partners Limited, acquired 10,119 shares on NASDAQ at $1.59 each. This transaction raised Cerrone's total holdings to 10,526,416 shares. OKYO Pharma, a clinical-stage biopharmaceutical company, is advancing its lead drug urcosimod, targeting neuropathic corneal pain (NCP) and inflammatory eye diseases. Urcosimod has demonstrated significant pain reduction in Phase 2 trials and is preparing for a larger Phase 2b/3 study involving approximately 150 subjects in the first half of 2026. The share acquisition signals insider confidence as OKYO pursues novel therapies for ocular diseases.
Go toTop